000			03754nam a22003615i 4500
001			81416
003			ES-MaUEC
005			20240611040137.0
007			cr nn 008mamaa
008			150425s2015 gw | s |||| 0|eng d
020			_a9783319179728
024	7		_a10.1007/978-3-319-17972-8 _2doi
050		4	_aRC271.E7 _bR47 2015 EB
082	0	4	_a614.5999
245	1	0	_aResistance to Aromatase Inhibitors in Breast Cancer _cedited by Alexey Larionov.
264		1	_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (XVI, 288 páginas) _b56 ilustraciones, 27 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v8
520			_aThe book brings together current knowledge about molecular and clinical aspects of resistance to aromatase inhibitors (AIs). The topics and features include: The history of development and clinical role of aromatase inhibitors in breast cancer. The structure and function of aromatase gene and protein, including tissue-specific splicing and regulation of the gene, crystal structure of the enzyme, functioning of its active site and structural basis for development of new aromatase inhibitors. Experimental and pre-clinical models of resistance to aromatase inhibitors (including cell lines and xenografts) as well as methods and results of measuring oestrogen concentrations in blood and tumour tissue of breast cancer patients. Diversity of molecular mechanisms of AI resistance, including (i) ligand-independent signalling through oestrogen receptor pathway, (ii) hypersensitivity to low concentrations of oestrogens, (iii) crosstalk with non-endocrine signalling (including PI3K/mTOR, IGF, GDNF and Myc pathways), (iv) involvement of oestrogen-induced apoptosis and tissue microenvironment (including inflammatory immune cells and adipocytes) as well as (v) the role of epigenetic mechanisms and pioneering factors in ER signalling and AI resistance. Molecular markers and multi-gene signatures to predict response to AIs, clinical trials aimed at preventing or overcoming resistance by combining AIs with novel targeted agents (including AI combinations with HER2, EGFR, mTOR, PI3K, Akt, CDK4/6, FGFR, HDAC, IGF-1, Src, proteosome- and angiogenic- targeting agents). A review of the effects and clinical indications of aromatase inhibitors beyond breast cancer. Many of the chapters provide extensive historical overviews to connect current knowledge with the history and inner logic of the field. The authorsâ€{u0D25}am includes world-leading experts, making the book an essential resource for scientists developing new treatments for breast cancer and for medics treating breast cancer patients with aromatase inhibitors.
650		7	_aCáncer _xInvestigación _2embne _9182523
700	1		_aLarionov, Alexey _eeditor literario _993820 _0Local _0http://id.loc.gov/authorities/names/no2002024148 _1http://viaf.org/viaf/355144782714564820475
710	2		_aSpringerLink (Online service) _0Local _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-17972-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12900060 _b10-10-17 _c18-01-16
942			_2lcc _cLE
945			_aRC261-271 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11569682 _z06-04-17
988	0	0	_aEBOOK, EBSPRINGER, GOBI_sep2018
988			_aEbook_one2one
998			_aSI _a_alco _a_vill _b10/2018 _cm _dz _ef _feng _ggw _h0
999			_c81416 _d81416 _x1